Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma

Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma

Source: 
CP Wire
snippet: 
  • Results from the trial demonstrated that combination treatment with Adcetris plus CHP was superior to the control arm for progression free survival (PFS)
  • All other key secondary endpoints were met
  •  A recent small study indicated that Adcetris used combination with other treatments may increase lung toxicity in children and young adults.
  • Adcetris generated approximately $640 million in 2017